The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science ...
Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill is included. Is chronic coughing or shortness of breath holding you back?
We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...
Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...
Chronic Obstructive Pulmonary Disease (COPD) is a chronic and irreversible lung condition that is a global public health problem. Globally, approximately 213 million people have COPD, and it was ...
Biomedical startups are taking aim at a deadly lung condition that has long lacked innovative treatments. Chronic obstructive pulmonary disease, caused by smoking and air pollution, hinders breathing ...
Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback